ATE164313T1 - Inaktivierte respiratorische synzytial-virus- impfstoffe - Google Patents
Inaktivierte respiratorische synzytial-virus- impfstoffeInfo
- Publication number
- ATE164313T1 ATE164313T1 AT94923619T AT94923619T ATE164313T1 AT E164313 T1 ATE164313 T1 AT E164313T1 AT 94923619 T AT94923619 T AT 94923619T AT 94923619 T AT94923619 T AT 94923619T AT E164313 T1 ATE164313 T1 AT E164313T1
- Authority
- AT
- Austria
- Prior art keywords
- virus
- inactivated
- immunogenic composition
- purified
- synzytial
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 abstract 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 abstract 1
- HEGSGKPQLMEBJL-RGDJUOJXSA-N octyl alpha-D-glucopyranoside Chemical compound CCCCCCCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RGDJUOJXSA-N 0.000 abstract 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 abstract 1
- 229960000380 propiolactone Drugs 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18551—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10274293A | 1993-08-06 | 1993-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE164313T1 true ATE164313T1 (de) | 1998-04-15 |
Family
ID=22291469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94923619T ATE164313T1 (de) | 1993-08-06 | 1994-08-04 | Inaktivierte respiratorische synzytial-virus- impfstoffe |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7083795B1 (de) |
| EP (1) | EP0714306B1 (de) |
| JP (1) | JP4053587B2 (de) |
| KR (1) | KR100402379B1 (de) |
| CN (1) | CN1103603C (de) |
| AT (1) | ATE164313T1 (de) |
| AU (1) | AU677090B2 (de) |
| BR (1) | BR9407182A (de) |
| CA (1) | CA2167274C (de) |
| DE (1) | DE69409243T2 (de) |
| DK (1) | DK0714306T3 (de) |
| ES (1) | ES2113670T3 (de) |
| GR (1) | GR3026619T3 (de) |
| RU (1) | RU2142817C1 (de) |
| WO (1) | WO1995004545A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4243491A1 (de) * | 1992-12-22 | 1994-06-23 | Behringwerke Ag | Verfahren zur Reinigung und Anreicherung von Rubella-Virus |
| RU2289425C2 (ru) * | 2004-12-09 | 2006-12-20 | Михаил Петрович Костинов | Способ профилактики заболеваний лор-органов и органов дыхательной системы, обусловленных вирусной и неспецифической бактериальной флорой у детей раннего возраста, рожденных от вич-инфицированных матерей |
| DK2590675T3 (en) * | 2010-07-07 | 2018-10-29 | Artificial Cell Tech Inc | ANTI-ANTI-COMPOSITIONS AND PROCEDURES FOR RESPIRATORY SYNCYTIAL VIRUS |
| AU2018390797B2 (en) * | 2017-12-19 | 2025-10-02 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
| KR20210018206A (ko) | 2018-04-03 | 2021-02-17 | 사노피 | 항원성 호흡기 세포융합 바이러스 폴리펩타이드 |
| CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| US20220340914A1 (en) * | 2019-12-10 | 2022-10-27 | Repligen Corporation | Methods of preparing viral vectors |
| JP2024503727A (ja) | 2021-01-20 | 2024-01-26 | アルト ニューロサイエンス，インコーポレーテッド | うつ病及び関連する状態の治療のための併用薬物戦略としてのｃＡＭＰシグナル伝達の強化 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517304A (en) * | 1980-07-01 | 1985-05-14 | National Research Development Corporation | Production of viral antigens |
| US4591505A (en) * | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
| US4664912A (en) | 1984-10-01 | 1987-05-12 | Wiktor Tadeusz J | Process for the large scale production of rabies vaccine |
| US4790987A (en) * | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US5200179A (en) * | 1987-09-28 | 1993-04-06 | Beecham Group P.L.C. | Vaccine |
| CA1332919C (en) * | 1987-09-28 | 1994-11-08 | Dale Bordt | Viral vaccine |
| US5223254A (en) * | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
| GB8914968D0 (en) | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
| IL105456A (en) | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
| TW275632B (de) * | 1992-04-21 | 1996-05-11 | American Cyanamid Co |
-
1994
- 1994-08-04 AT AT94923619T patent/ATE164313T1/de active
- 1994-08-04 KR KR1019960700607A patent/KR100402379B1/ko not_active Expired - Fee Related
- 1994-08-04 CN CN94193703A patent/CN1103603C/zh not_active Expired - Lifetime
- 1994-08-04 JP JP50612395A patent/JP4053587B2/ja not_active Expired - Fee Related
- 1994-08-04 AU AU73801/94A patent/AU677090B2/en not_active Ceased
- 1994-08-04 CA CA002167274A patent/CA2167274C/en not_active Expired - Fee Related
- 1994-08-04 US US08/583,124 patent/US7083795B1/en not_active Expired - Fee Related
- 1994-08-04 RU RU96105905A patent/RU2142817C1/ru not_active IP Right Cessation
- 1994-08-04 EP EP94923619A patent/EP0714306B1/de not_active Expired - Lifetime
- 1994-08-04 ES ES94923619T patent/ES2113670T3/es not_active Expired - Lifetime
- 1994-08-04 DK DK94923619T patent/DK0714306T3/da active
- 1994-08-04 BR BR9407182A patent/BR9407182A/pt not_active Application Discontinuation
- 1994-08-04 WO PCT/CA1994/000425 patent/WO1995004545A1/en not_active Ceased
- 1994-08-04 DE DE69409243T patent/DE69409243T2/de not_active Expired - Lifetime
-
1998
- 1998-04-10 GR GR980400815T patent/GR3026619T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69409243T2 (de) | 1998-08-06 |
| DE69409243D1 (de) | 1998-04-30 |
| AU677090B2 (en) | 1997-04-10 |
| BR9407182A (pt) | 1996-09-17 |
| CN1103603C (zh) | 2003-03-26 |
| WO1995004545A1 (en) | 1995-02-16 |
| CN1133013A (zh) | 1996-10-09 |
| CA2167274C (en) | 2007-11-27 |
| KR960703618A (ko) | 1996-08-31 |
| RU2142817C1 (ru) | 1999-12-20 |
| ES2113670T3 (es) | 1998-05-01 |
| AU7380194A (en) | 1995-02-28 |
| DK0714306T3 (da) | 1998-10-19 |
| JPH09501912A (ja) | 1997-02-25 |
| EP0714306B1 (de) | 1998-03-25 |
| EP0714306A1 (de) | 1996-06-05 |
| GR3026619T3 (en) | 1998-07-31 |
| JP4053587B2 (ja) | 2008-02-27 |
| US7083795B1 (en) | 2006-08-01 |
| CA2167274A1 (en) | 1995-02-16 |
| KR100402379B1 (ko) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2684792A (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| BR9510263A (pt) | Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas | |
| WO2004001007A3 (en) | Buffered formulations for concentrating antibodies and methods of use thereof | |
| DK0777490T3 (da) | Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans | |
| MX9306841A (es) | Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos. | |
| ES465514A1 (es) | Procedimiento para la obtencion de derivados de glucosamina. | |
| HU229368B1 (en) | Novel vaccine composition | |
| ES2074950A1 (es) | Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda. | |
| FI905184A0 (fi) | Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3. | |
| ATE164313T1 (de) | Inaktivierte respiratorische synzytial-virus- impfstoffe | |
| ATE179614T1 (de) | Herpes simplex virus vp16 impfstoffe | |
| DE69940406D1 (de) | Ine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält | |
| EP0480949A1 (de) | Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung. | |
| DE69531793D1 (de) | Immunogene zubereitungen | |
| ES379641A1 (es) | Procedimiento de produccion de antigenos inactivos para preparados farmaceuticos. | |
| ATE354370T1 (de) | Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen | |
| DE68923169D1 (de) | Verwendung von fluor enthaltenden Pyridoncarbonsäure-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von HIV infektionen. | |
| WO1999053950A3 (en) | Live vaccines and methods of treatment therewith | |
| van der Noordaa et al. | Primary vaccination with an attenuated strain of vaccinia virus | |
| ES515472A0 (es) | Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis. | |
| JPS6456620A (en) | Production of hemorrhagic fever with renal syndrome virus antigen and vaccine and diagnostic agent using said antigen | |
| EP0591384A4 (de) | Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1. | |
| Greenberg et al. | " Emotional disclosure about traumas and its relation to health: Effects of previous disclosure and trauma severity": Correction to Greenberg and Stone. | |
| JPS56115724A (en) | Prophilaxis and remedy for avian infectious coryza |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |